查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965362

Omega-3處方藥市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、應用、分銷管道、地區和競爭格局分類，2021-2031年

Omega 3 Prescription Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug type, By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球Omega-3處方藥市場預計將從 2025 年的 22.1 億美元成長到 2031 年的 36.9 億美元，複合年成長率為 8.92%。

這些藥用級製劑由二十碳五烯酸 (EPA) 和二十二碳六烯酸 (DHA) 的純化乙酯或羧酸組成，主要用於治療重度高高三酸甘油脂血症。市場成長的主要促進因素包括全球心血管疾病盛行率的上升以及醫療專業人員擴大採用預防性血脂管理策略。此外，人口老化和全球肥胖率上升等人口結構變化也使得人們對有效治療方案的需求日益成長，進一步推動了對這些受監管藥物的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 22.1億美元
市場規模：2031年 36.9億美元
複合年成長率：2026-2031年 8.92%
成長最快的細分市場 高三酸甘油脂血症節段
最大的市場 北美洲

然而，市場成長面臨許多挑戰，包括提煉藥用級魚油以滿足嚴格監管標準的供應鏈複雜性和高成本。這些嚴格的品質要求往往導致庫存短缺和價格波動，進而影響全球產品供應。根據美國環保署（EPA）和國際組織關於DHA Omega-3的數據，2024年全球Omega-3原料總量將達到131,183噸，比上年增加2.5%。同時，市場總值將達到約24億美元，成長10.2%。

市場促進因素

推動全球Omega-3處方藥市場成長的主要因素是全球心血管疾病和肥胖症發生率的激增。由於高三酸甘油脂血症與超重密切相關，因此有效的藥物干預對於降低胰臟炎和心肌梗塞等疾病的風險至關重要。顯著的人口趨勢進一步加劇了這項需求。根據世界肥胖聯盟於2024年3月發布的《2024年世界肥胖地圖集》，預計2035年，全球肥胖成年人口將達到15.3億。這些疾病的高死亡率凸顯了血脂管理的重要性，美國心臟協會發布的《2024年心血管和中風統計更新》也支持了這一觀點，該報告指出，2021年美國有931,578人死於心血管疾病。

此外，在積極的監管核准推動下，隨著患者和醫療保健提供者加速從營養補充劑轉向處方治療，市場正在不斷擴張。由於高純度、經政府批准的製劑具有更高的生物利用度和經證實能降低三酸甘油酯水平的臨床療效，醫療保健專業人員越來越傾向於選擇此類製劑​​而非非處方藥。這種向藥物治療的轉變正在對受監管市場的商業性表現產生顯著影響。例如，Amarin公司於2024年10月發布的2024年第三季財報顯示，其VAZKEPA在歐洲的銷售額環比成長了19%，這表明處方Omega-3療法正在被主要的國際醫療保健系統迅速採用。

市場挑戰

全球Omega-3處方藥市場主要受制於複雜的供應鏈和高昂的生產成本。與合成藥物不同，這類藥物嚴重依賴海洋來源的原料，尤其是粗魚油，而這些原料需要昂貴的大規模精煉製程才能達到藥用級純度要求。這種對自然資源的依賴使得生產商極易受到不可預測的環境條件和嚴格的捕撈配額的影響，導致價格和供應大幅波動。因此，企業難以維持穩定的庫存水平，造成生產瓶頸、供應延遲，並阻礙醫療機構將這些治療方法用於長期治療。

近期產業波動凸顯了這套原料供應鏈的脆弱性。根據國際魚油生產商聯合會（IFFO）預測，2024年全球魚油產量將年增12%，這顯示在經歷了嚴重的供不應求短缺之後，市場對氣候變遷高度敏感。原物料供應的快速波動迫使生產商承擔高昂的避險和倉儲營運成本，以確保供應的連續性。這些財務壓力最終會波及整個供應鏈，導致藥品價格持續高企，並限制了注重成本的醫療保健系統獲得市場進入。

市場趨勢

學名藥（例如二十碳五烯酸乙酯）的激增從根本上改變了競爭格局。尤其在美國，市場主導地位的喪失導致價格大幅下降。這些低價替代品的進入崩壞了曾經由品牌藥主導的市場，迫使現有生產商縮減商業活動，同時透過降價擴大病患的用藥管道。這種商品化帶來的巨大財務影響在近期主要品牌藥的業績中得到了清楚的體現。根據Amarin公司2024年10月發布的2024年第三季財報，其在美國的旗艦處方藥淨銷售額從去年同期的6,240萬美元下降至3,060萬美元。這一下滑直接歸因於非專利競爭對手市場佔有率的擴大。

同時，為彌補北美和歐洲市場的飽和，各公司正加速向亞太市場進行策略性商業擴張。這一趨勢標誌著企業關注的焦點正從傳統的北美和歐洲市場轉移，同時，企業也在那些心血管疾病高危險群眾多且未接受治療的國家/地區獲得監管部門的核准。中國在這擴張過程中扮演著至關重要的角色，為處方降血脂藥物提供了新的患者群體。正如Amarin公司在2024年7月發布的公告《Amarin合作夥伴Edding Farm的VASCEPA在中國當地獲得監管核准》中所指出的，中國估計有3.3億心血管疾病患者，這凸顯了該地區在未來行業產生收入的關鍵作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球Omega-3處方藥市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類型（Vascepa、Lovaza 等）
    • 依應用（高三酸甘油脂血症，其他）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美Omega-3處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲Omega-3處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區Omega-3處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東及非洲地區Omega-3處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲Omega-3處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球Omega-3處方藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc
  • Amarin Pharmaceuticals Ireland Ltd.
  • GSK plc（GlaxoSmithKline plc）
  • Natrapharm, Inc.（Patriot Pharmaceutical Corp.）
  • Viatris, Inc.
  • Grupo Ferrer Internacional, SA
  • Camber Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Group
  • Hikma Pharmaceuticals PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24047

The Global Omega 3 Prescription Drugs Market is projected to expand from USD 2.21 billion in 2025 to USD 3.69 billion by 2031, registering a compound annual growth rate of 8.92%. These pharmaceutical-grade formulations, composed of purified ethyl esters or carboxylic acids sourced from eicosapentaenoic and docosahexaenoic acids, are prescribed primarily to treat severe hypertriglyceridemia. Key factors driving market growth include the rising prevalence of cardiovascular conditions worldwide and the growing implementation of preventative lipid management strategies by medical professionals. Furthermore, demographic changes such as an aging global population and increasing obesity rates create a strong need for effective therapeutic options, thereby reinforcing the demand for these regulated medical treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.21 Billion
Market Size 2031USD 3.69 Billion
CAGR 2026-20318.92%
Fastest Growing SegmentHypertriglyceridemia Segment
Largest MarketNorth America

However, market growth faces significant hurdles due to supply chain complications and high production costs involved in refining raw fish oils to strictly regulated pharmaceutical standards. These rigorous quality demands frequently result in stock shortages and fluctuating prices, which subsequently affect global product availability. Data from the Global Organization for EPA and DHA Omega-3s indicates that in 2024, the total global volume of omega-3 ingredients hit 131,183 metric tons, marking a 2.5% increase from the previous year, while the total market value grew by 10.2% to reach roughly $2.4 billion.

Market Driver

The primary forces accelerating the Global Omega 3 Prescription Drugs Market are the surging global rates of cardiovascular disease and obesity. Since elevated triglyceride levels are closely associated with excess body weight, effective pharmaceutical interventions are essential to reduce risks such as pancreatitis and myocardial infarction. This demand is further amplified by significant demographic trends; the World Obesity Federation's 'World Obesity Atlas 2024', released in March 2024, estimates that the global population of adults with obesity will rise to 1.53 billion by 2035. The high mortality rate linked to these conditions emphasizes the critical need for lipid management, a fact highlighted by the American Heart Association's '2024 Heart Disease and Stroke Statistics Update', which noted that cardiovascular disease caused 931,578 deaths in the United States in 2021.

Additionally, the market is growing as patients and providers increasingly transition from dietary supplements to prescription-grade therapies, aided by favorable regulatory endorsements. Medical professionals increasingly prefer high-purity, government-authorized formulations over over-the-counter alternatives because of their superior bioavailability and demonstrated clinical effectiveness in reducing triglyceride levels. This movement toward medicalized treatment is clearly influencing commercial results in regulated markets. For instance, Amarin Corporation's 'Third Quarter 2024 Financial Results' from October 2024 reported a 19% sequential increase in VAZKEPA sales in Europe, demonstrating the rapid adoption of prescription omega-3 therapies within major international healthcare systems.

Market Challenge

The expansion of the Global Omega 3 Prescription Drugs Market is substantially constrained by supply chain intricacies and substantial production costs. In contrast to synthetic medicines, these drugs rely heavily on marine-sourced raw materials, particularly crude fish oil, which necessitates expensive and extensive refinement to meet pharmaceutical-grade purity requirements. This dependence on natural resources subjects manufacturers to significant volatility regarding price and availability, often caused by unpredictable environmental conditions and strict fishing quotas. As a result, companies struggle to maintain stable inventories, causing production bottlenecks that delay supply and deter healthcare providers from depending on these therapies for long-term care.

Recent industry fluctuations emphasize the vulnerability of this raw material supply chain. According to IFFO, cumulative global fish oil production in 2024 was estimated to show a 12% year-on-year increase, a figure that highlights the market's acute sensitivity to climatic events following a period of severe shortage. Such drastic swings in raw material availability compel manufacturers to absorb higher operational costs related to hedging and storage to guarantee continuity. These financial pressures are eventually passed down the supply chain, sustaining high drug prices and restricting market access within cost-conscious healthcare systems.

Market Trends

The competitive environment is being fundamentally altered by the widespread availability of generic icosapent ethyl products, especially in the United States where the loss of market exclusivity has led to sharp price reductions. The entry of these more affordable alternatives has broken the monopoly once held by branded drugs, compelling established manufacturers to shrink their commercial operations while simultaneously expanding patient access through lower prices. The significant financial toll of this commoditization is clear in the recent performance of leading brands; Amarin Corporation's 'Third Quarter 2024 Financial Results' from October 2024 revealed that U.S. net product revenue for its primary prescription drug fell to $30.6 million from $62.4 million in the same period the previous year, a decline directly caused by the growing market share of generic rivals.

Concurrently, companies are accelerating strategic commercial expansion into Asia-Pacific markets to compensate for saturation in Western regions. This trend involves achieving regulatory successes in nations with vast, untreated populations at risk of cardiovascular disease, shifting focus beyond traditional North American and European markets. China has become a pivotal area for this expansion, presenting a substantial new patient base for prescription lipid therapies. As noted in Amarin Corporation's July 2024 announcement titled 'Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA in Mainland China', the country is home to an estimated 330 million patients with cardiovascular disease, highlighting the region's essential role in generating future industry revenue.

Key Market Players

  • Abbott Laboratories Inc
  • Amarin Pharmaceuticals Ireland Ltd.
  • GSK plc (GlaxoSmithKline plc)
  • Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
  • Viatris, Inc.
  • Grupo Ferrer Internacional, S.A.
  • Camber Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Group
  • Hikma Pharmaceuticals PLC

Report Scope

In this report, the Global Omega 3 Prescription Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omega 3 Prescription Drugs Market, By Drug type

  • Vascepa
  • Lovaza
  • Others

Omega 3 Prescription Drugs Market, By Application

  • Hypertriglyceridemia
  • Others

Omega 3 Prescription Drugs Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Omega 3 Prescription Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Omega 3 Prescription Drugs Market.

Available Customizations:

Global Omega 3 Prescription Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omega 3 Prescription Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug type (Vascepa, Lovaza, Others)
    • 5.2.2. By Application (Hypertriglyceridemia, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Omega 3 Prescription Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug type
    • 6.2.2. By Application
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Omega 3 Prescription Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Omega 3 Prescription Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Omega 3 Prescription Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Omega 3 Prescription Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug type
    • 7.2.2. By Application
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Omega 3 Prescription Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Omega 3 Prescription Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Omega 3 Prescription Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Omega 3 Prescription Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Omega 3 Prescription Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Omega 3 Prescription Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug type
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Omega 3 Prescription Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Omega 3 Prescription Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Omega 3 Prescription Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Omega 3 Prescription Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Omega 3 Prescription Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Omega 3 Prescription Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug type
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Omega 3 Prescription Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Omega 3 Prescription Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Omega 3 Prescription Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. South America Omega 3 Prescription Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug type
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Omega 3 Prescription Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Omega 3 Prescription Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Omega 3 Prescription Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Omega 3 Prescription Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amarin Pharmaceuticals Ireland Ltd.
  • 15.3. GSK plc (GlaxoSmithKline plc)
  • 15.4. Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
  • 15.5. Viatris, Inc.
  • 15.6. Grupo Ferrer Internacional, S.A.
  • 15.7. Camber Pharmaceuticals, Inc.
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Zydus Group
  • 15.10. Hikma Pharmaceuticals PLC

16. Strategic Recommendations

17. About Us & Disclaimer